Ardelyx Inc (41X.SG)
| Previous close | 5.86 |
| Open | 5.90 |
| Bid | 6.01 x 0 |
| Ask | 6.06 x 0 |
| Day's range | 5.83 - 6.06 |
| 52-week range | 2.97 - 9.46 |
| Volume | |
| Avg. volume | 460 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksArdelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.Ardelyx's (NASDAQ:ARDX) investors will be pleased with their favorable 91% return over the last five years
While Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders are probably generally happy, the stock hasn't had particularly good...
GlobeNewswireArdelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2024. To part
